Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-03-19
    E.g., 2018-03-19


50193 items
12:00 AM, Jan 27, 2000  |  BC Extra | Clinical News

Discovery Laboratories begins and halts Phase IIIs

DSCO began U.S. Phase III testing of its Surfaxin pulmonary surfactant in 200 newborns with meconium aspiration syndrome. The study will compare Surfaxin to standard care. Separately, DSCO halted its U.S. Phase III trial in...
12:00 AM, Jan 26, 2000  |  BC Extra | Clinical News

Biomira presents BLP25 data

Biomira (TSE:BRA; BIOM) reported data from a Phase I study showing that its BLP25 cancer vaccine triggered a cytotoxic T cell response against cancer cells in five of 12 evaluable non-small cell lung cancer patients....
12:00 AM, Jan 26, 2000  |  BC Extra | Clinical News

Searle starts Phase III study

Searle began a multinational Phase III trial of its eplerenone selective aldosterone receptor antagonists in 6,200 patients to treat heart failure due to myocardial infarction....
12:00 AM, Jan 26, 2000  |  BC Extra | Company News

Cell Pathways in Aptosyn agreements

CLPA signed agreements with Innovex, Livingston Healthcare, and Lash Group for U.S. sales and distribution of its Aptosyn exisulind oral medication to treat familial adenomatous polyposis (FAP). Innovex, a business unit of Quintiles (QTRN), will...
12:00 AM, Jan 26, 2000  |  BC Extra | Company News

Myriad in asthma genomics deal

MYGN and Biotecne (Caglliari, Italy) will collect DNA samples, hospital records and family pedigree data from the original families in Sardinia to find genes relating to asthma. The deal is planned to expand into depression,...
12:00 AM, Jan 26, 2000  |  BC Extra | Company News

Quark and Shionogi collaborate

Quark Biotech (Pleasanton, Calif.) will use its genomics and bioinformatics technologies to discover, identify and determine the function of genes related to osteoarthritis. Shionogi (Osaka, Japan) will develop and manufacture resulting pharmaceutical and diagnostic candidates....
12:00 AM, Jan 26, 2000  |  BC Extra | Company News

Cell Genesys license deal with Clontech

CEGE non-exclusively licensed its retroviral gene delivery technology to Clontech. Clontech, a subsidiary of Becton Dickinson, will use the technology in its research kits, and CEGE will receive royalties on sales....
12:00 AM, Jan 26, 2000  |  BC Extra | Company News

SkyePharma gets milestone

Sanofi- Synthelabo (Paris, France) received marketing approval in Denmark, France, the Netherlands and Switzerland for Xatral alfuzosin to treat enlarged prostate glands. The approval triggered a milestone payment to SkyePharma (LSE:SKP; SKYE), whose Geomatrix oral...
12:00 AM, Jan 26, 2000  |  BC Extra | Company News

Pain collaboration completed

Cambridge Drug Discovery ( Cambridge, U.K.) and Parke-Davis Neuroscience Research Centre ( Cambridge, U.K.) completed a high throughput screening collaboration to identify compounds for a receptor target associated with pain....
12:00 AM, Jan 26, 2000  |  BC Extra | Top Story

Dendreon starts Phase III

Dendreon (Seattle, Wash.) began placebo-controlled U.S. Phase III testing of its dendritic cell therapy in 240 patients with advanced prostate cancer. The study will examine whether three treatments of the immunotherapy over 30 days delays...